Development of a novel β-cell specific promoter system for the identification of insulin-producing cells in in vitro cell cultures

Takuya Fukazawa, Junji Matsuoka, Yoshio Naomoto, Toru Nakai, Mary L. Durbin, Itaru Kojima, Jonathan R T Lakey, Noriaki Tanaka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Recently, it has been reported that islet transplantation into patients with Type 1 diabetes may achieve insulin independence for a year or longer [Shapiro et al., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med. 343 (2000) 230-238]. However, the amount of donor islet tissue is limited, therefore, multiple approaches are being explored to generate insulin-producing cells in vitro. Some promising results have been obtained using mouse and human stem cells and progenitor cells [Soria et al., From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus, Diabetologia. 4 (2001) 407-415; Lechner et al., Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus, Am J Physiol Endocrinol Metab. 284 (2003) 259-266; Bonner-Weir et al., In vitro cultivation of human islets from expanded ductal tissue, Proc Natl Acad Sci U S A, 97 (2000) 7999-8004; Assady et al., Insulin production by human embryonic stem cells, 50 (2001) Diabetes 1691-1697]. However, the efficiency of obtaining populations with high numbers of differentiated cells has been poor. In order to improve the efficiency of producing and selecting insulin-producing cells from undifferentiated cells, we have designed a novel β-cell specific and glucose responsive promoter system designated pGL3.hINS-363 3×. This artificial promoter system exhibits significant luciferase activity not only in insulin-producing MIN6 m9 cells but also in isolated human islets. The pGL3.hINS-363 3× construct shows no activity in non-insulin-producing cells in low glucose conditions (2 mM glucose) but demonstrates significant activity and β-cell specificity in high glucose conditions (16 mM glucose). Furthermore, pGL3.hINS-363 3× shows significant promoter activity in differentiated AR42J cells that can produce insulin after activin A and betacellulin treatment. Here, we describe a novel β-cell specific and glucose responsive artificial promoter system designed for analyzing and sorting β-like insulin-producing cells that have differentiated from stem cells or other progenitor cells.

Original languageEnglish
Pages (from-to)3404-3412
Number of pages9
JournalExperimental Cell Research
Volume312
Issue number17
DOIs
Publication statusPublished - Oct 15 2006

Fingerprint

Cell Culture Techniques
Insulin
Stem Cells
Glucose
Islets of Langerhans Transplantation
Type 1 Diabetes Mellitus
Diabetes Mellitus
In Vitro Techniques
Immunosuppressive Agents
Cell- and Tissue-Based Therapy
Luciferases
Glucocorticoids
Cell Count
Tissue Donors
Therapeutics
Population

Keywords

  • β-cell
  • Diabetes mellitus
  • Differentiation
  • Insulin promoter
  • Islet transplantation
  • Stem cell
  • Transcription factor

ASJC Scopus subject areas

  • Cell Biology

Cite this

Development of a novel β-cell specific promoter system for the identification of insulin-producing cells in in vitro cell cultures. / Fukazawa, Takuya; Matsuoka, Junji; Naomoto, Yoshio; Nakai, Toru; Durbin, Mary L.; Kojima, Itaru; Lakey, Jonathan R T; Tanaka, Noriaki.

In: Experimental Cell Research, Vol. 312, No. 17, 15.10.2006, p. 3404-3412.

Research output: Contribution to journalArticle

Fukazawa, Takuya ; Matsuoka, Junji ; Naomoto, Yoshio ; Nakai, Toru ; Durbin, Mary L. ; Kojima, Itaru ; Lakey, Jonathan R T ; Tanaka, Noriaki. / Development of a novel β-cell specific promoter system for the identification of insulin-producing cells in in vitro cell cultures. In: Experimental Cell Research. 2006 ; Vol. 312, No. 17. pp. 3404-3412.
@article{6a5e1e1447d94d038543adebd00a9306,
title = "Development of a novel β-cell specific promoter system for the identification of insulin-producing cells in in vitro cell cultures",
abstract = "Recently, it has been reported that islet transplantation into patients with Type 1 diabetes may achieve insulin independence for a year or longer [Shapiro et al., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med. 343 (2000) 230-238]. However, the amount of donor islet tissue is limited, therefore, multiple approaches are being explored to generate insulin-producing cells in vitro. Some promising results have been obtained using mouse and human stem cells and progenitor cells [Soria et al., From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus, Diabetologia. 4 (2001) 407-415; Lechner et al., Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus, Am J Physiol Endocrinol Metab. 284 (2003) 259-266; Bonner-Weir et al., In vitro cultivation of human islets from expanded ductal tissue, Proc Natl Acad Sci U S A, 97 (2000) 7999-8004; Assady et al., Insulin production by human embryonic stem cells, 50 (2001) Diabetes 1691-1697]. However, the efficiency of obtaining populations with high numbers of differentiated cells has been poor. In order to improve the efficiency of producing and selecting insulin-producing cells from undifferentiated cells, we have designed a novel β-cell specific and glucose responsive promoter system designated pGL3.hINS-363 3×. This artificial promoter system exhibits significant luciferase activity not only in insulin-producing MIN6 m9 cells but also in isolated human islets. The pGL3.hINS-363 3× construct shows no activity in non-insulin-producing cells in low glucose conditions (2 mM glucose) but demonstrates significant activity and β-cell specificity in high glucose conditions (16 mM glucose). Furthermore, pGL3.hINS-363 3× shows significant promoter activity in differentiated AR42J cells that can produce insulin after activin A and betacellulin treatment. Here, we describe a novel β-cell specific and glucose responsive artificial promoter system designed for analyzing and sorting β-like insulin-producing cells that have differentiated from stem cells or other progenitor cells.",
keywords = "β-cell, Diabetes mellitus, Differentiation, Insulin promoter, Islet transplantation, Stem cell, Transcription factor",
author = "Takuya Fukazawa and Junji Matsuoka and Yoshio Naomoto and Toru Nakai and Durbin, {Mary L.} and Itaru Kojima and Lakey, {Jonathan R T} and Noriaki Tanaka",
year = "2006",
month = "10",
day = "15",
doi = "10.1016/j.yexcr.2006.07.015",
language = "English",
volume = "312",
pages = "3404--3412",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "17",

}

TY - JOUR

T1 - Development of a novel β-cell specific promoter system for the identification of insulin-producing cells in in vitro cell cultures

AU - Fukazawa, Takuya

AU - Matsuoka, Junji

AU - Naomoto, Yoshio

AU - Nakai, Toru

AU - Durbin, Mary L.

AU - Kojima, Itaru

AU - Lakey, Jonathan R T

AU - Tanaka, Noriaki

PY - 2006/10/15

Y1 - 2006/10/15

N2 - Recently, it has been reported that islet transplantation into patients with Type 1 diabetes may achieve insulin independence for a year or longer [Shapiro et al., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med. 343 (2000) 230-238]. However, the amount of donor islet tissue is limited, therefore, multiple approaches are being explored to generate insulin-producing cells in vitro. Some promising results have been obtained using mouse and human stem cells and progenitor cells [Soria et al., From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus, Diabetologia. 4 (2001) 407-415; Lechner et al., Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus, Am J Physiol Endocrinol Metab. 284 (2003) 259-266; Bonner-Weir et al., In vitro cultivation of human islets from expanded ductal tissue, Proc Natl Acad Sci U S A, 97 (2000) 7999-8004; Assady et al., Insulin production by human embryonic stem cells, 50 (2001) Diabetes 1691-1697]. However, the efficiency of obtaining populations with high numbers of differentiated cells has been poor. In order to improve the efficiency of producing and selecting insulin-producing cells from undifferentiated cells, we have designed a novel β-cell specific and glucose responsive promoter system designated pGL3.hINS-363 3×. This artificial promoter system exhibits significant luciferase activity not only in insulin-producing MIN6 m9 cells but also in isolated human islets. The pGL3.hINS-363 3× construct shows no activity in non-insulin-producing cells in low glucose conditions (2 mM glucose) but demonstrates significant activity and β-cell specificity in high glucose conditions (16 mM glucose). Furthermore, pGL3.hINS-363 3× shows significant promoter activity in differentiated AR42J cells that can produce insulin after activin A and betacellulin treatment. Here, we describe a novel β-cell specific and glucose responsive artificial promoter system designed for analyzing and sorting β-like insulin-producing cells that have differentiated from stem cells or other progenitor cells.

AB - Recently, it has been reported that islet transplantation into patients with Type 1 diabetes may achieve insulin independence for a year or longer [Shapiro et al., Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen, N Engl J Med. 343 (2000) 230-238]. However, the amount of donor islet tissue is limited, therefore, multiple approaches are being explored to generate insulin-producing cells in vitro. Some promising results have been obtained using mouse and human stem cells and progenitor cells [Soria et al., From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus, Diabetologia. 4 (2001) 407-415; Lechner et al., Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus, Am J Physiol Endocrinol Metab. 284 (2003) 259-266; Bonner-Weir et al., In vitro cultivation of human islets from expanded ductal tissue, Proc Natl Acad Sci U S A, 97 (2000) 7999-8004; Assady et al., Insulin production by human embryonic stem cells, 50 (2001) Diabetes 1691-1697]. However, the efficiency of obtaining populations with high numbers of differentiated cells has been poor. In order to improve the efficiency of producing and selecting insulin-producing cells from undifferentiated cells, we have designed a novel β-cell specific and glucose responsive promoter system designated pGL3.hINS-363 3×. This artificial promoter system exhibits significant luciferase activity not only in insulin-producing MIN6 m9 cells but also in isolated human islets. The pGL3.hINS-363 3× construct shows no activity in non-insulin-producing cells in low glucose conditions (2 mM glucose) but demonstrates significant activity and β-cell specificity in high glucose conditions (16 mM glucose). Furthermore, pGL3.hINS-363 3× shows significant promoter activity in differentiated AR42J cells that can produce insulin after activin A and betacellulin treatment. Here, we describe a novel β-cell specific and glucose responsive artificial promoter system designed for analyzing and sorting β-like insulin-producing cells that have differentiated from stem cells or other progenitor cells.

KW - β-cell

KW - Diabetes mellitus

KW - Differentiation

KW - Insulin promoter

KW - Islet transplantation

KW - Stem cell

KW - Transcription factor

UR - http://www.scopus.com/inward/record.url?scp=33748633162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748633162&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2006.07.015

DO - 10.1016/j.yexcr.2006.07.015

M3 - Article

C2 - 16934249

AN - SCOPUS:33748633162

VL - 312

SP - 3404

EP - 3412

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 17

ER -